Search This Blog

Wednesday, November 30, 2022

BioXcel starts Phase 3 Trial in Bipolar/Schizophrenia Treatment

 SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use

Top-line pivotal data expected in 1H 2023

Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. 1-4


https://finance.yahoo.com/news/bioxcel-therapeutics-announces-first-patients-120000182.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.